[Effect of a conjugate of adriamycin and an antibody to human alpha-fetoprotein (AFP) on AFP-producing hepatic tumors].
We have studied the effect of an anti-FP antibody coupled via a dextran bridge to adriamycin on six AFP-producing liver tumors (3 cases with hepatoma and 3 cases with liver metastases from an AFP-producing gastric cancer). Results have revealed that MR was observed in 2 out the 5 of surviving evaluated cases. The toxicity of this conjugate was not evident in all cases, except for a low-grade fever. Further, an autopsy revealed no remarkable change in the histology of the case that had ended in death. These results indicate that this conjugate can be considered one of the treatment therapies available for a nonresectable AFP-producing tumor.
Takahashi
Y
Y
Dept. of Surgery, Kanazawa Univ.
Ueno
M
M
Mai
M
M
Tsukada
Y
Y
D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D000922:Immunotoxins / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000556:secondary; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000378:metabolism; D000509:alpha-Fetoproteins / Q000096:biosynthesis / Q000276:immunology*
D000922:Immunotoxins; D000509:alpha-Fetoproteins; D004317:Doxorubicin